The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals ...

REPLY: In our recent letter to the editor, we discussed the evolving preclinical testing requirements for PET drugs at the Food and Drug Administration (FDA) ([1][1]). In particular, we highlighted ...

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

Owen Witte, MD, is recognized for multiple seminal contributions over the past 50 years impacting our understanding of human leukemias, immune disorders, and epithelial cancers, which have defined new ...

223Ra-dichloride (223Ra) is an approved therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. After an initial course of 6 ...

The gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate cancer, breast cancer, small cell and non–small cell lung cancer, uterine and ovarian cancer, ...

Heat shock protein 90 (Hsp90) is essential for maintaining cellular proteostasis and may play an important role in the development of neurodegenerative proteinopathies. Therefore, we aimed to develop ...

We introduce a unique bioanalytic hybrid system for the preclinical assessment of radiotracer candidates, combining a 3-dimensional cell culture on an artificial extracellular matrix functioning as a ...

Single-time-point (STP) image-based dosimetry offers a more convenient approach for clinical practice in radiopharmaceutical therapy (RPT) compared with conventional multiple-time-point image-based ...

Prostate-specific membrane antigen (PSMA)–targeted radiopharmaceutical therapy has demonstrated promising potential for treating metastatic castration-resistant prostate cancer. Recently, ...